Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 36
- Registration Number
- NCT00444678
- Locations
- 🇺🇸
New York University Langone Medical Center, New York, New York, United States
🇺🇸Bellevue Hospital, New York, New York, United States
Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- PD Dr. med. Volker Heinemann
- Target Recruit Count
- 280
- Registration Number
- NCT00440167
Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT00438256
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- Japan Breast Cancer Research Network
- Target Recruit Count
- 142
- Registration Number
- NCT00438100
- Locations
- 🇯🇵
The University of Tokyo Hospital, Tokyo, Japan
🇯🇵Kyushu Central Hospital, Fukuoka, Japan
🇯🇵Hirosaki University Hospital, Hirosaki, Japan
Brain Metastases In ErbB2-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 22
- Registration Number
- NCT00437073
- Locations
- 🇸🇪
GSK Investigational Site, Uppsala, Sweden
Enzastaurin in Combination of Capecitabine to Treat Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 86
- Registration Number
- NCT00437294
- Locations
- 🇿🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durban, South Africa
A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-02-15
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 442
- Registration Number
- NCT00435409
- Locations
- 🇬🇧
Pfizer Investigational Site, Worthing, United Kingdom
Capecitabine Plus Radiotherapy for Local Relapse Breast Cancer With Negative Her2 Tumours
- First Posted Date
- 2007-02-14
- Last Posted Date
- 2019-02-21
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 1
- Registration Number
- NCT00434941
- Locations
- 🇪🇸
Hospital Infanta Cristina, Badajoz, Spain
🇪🇸Hospital Universitario de la Princesa, Madrid, Spain
🇪🇸Hospital Clínico Universitario San Carlos, Madrid, Spain
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 33
- Registration Number
- NCT00433550
- Locations
- 🇺🇸
Medcenter One Hospital Cancer Care Center, Bismarck, North Dakota, United States
🇺🇸Regions Hospital Cancer Care Center, Saint Paul, Minnesota, United States
🇺🇸Toledo Hospital, Toledo, Ohio, United States
Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2009-09-28
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 144
- Registration Number
- NCT00431106
- Locations
- 🇬🇷
401 Military Hospital of Athens, Athens, Greece
🇬🇷University General Hospital of Alexandroupolis, Dept. of Medical Oncology, Alexandroupolis, Greece
🇬🇷"IASO" General Hospital of Athens, 1st Dept. of Medical Oncology, Athens, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.